Myelogenous Leukemia, Chronic Clinical Trial
Official title:
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
The goal of this research is to see if giving the drug SCH66336 by mouth can improve the disease in patients with chronic or accelerated phase CML. The safety of this treatment will also be studied.
Objectives for this study are two-fold:
1. To determine the efficacy of SCH66336 in patients with chronic phase and accelerated
phase CML in relation to response rate, duration of response, and survival.
2. To assess the toxicity of SCH66366 in these patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02736721 -
Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)
|
Phase 3 | |
| Completed |
NCT00179764 -
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
|
N/A | |
| Completed |
NCT00111683 -
MK0457 in Patients With Leukemia (0457-003)
|
Phase 1 | |
| Completed |
NCT00471497 -
A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
|
Phase 3 | |
| Active, not recruiting |
NCT01503502 -
A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
|
Phase 2 | |
| Active, not recruiting |
NCT00718263 -
Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)
|
Phase 3 |